13-09J Update: Management of Menopausal and Postmenopausal Symptoms

1 CE, 1 Rx

Donna Duvall, RN, MN, WHCNP
Private Practice
San Diego, California

David M. Plourd, MD, FACOG
Clinical Instructor, Department of Obstetrics and Gynecology
University of California, San Diego
San Diego, California

Intended Audience
This continuing education (CE) activity has been designated to meet the educational needs of nurse practitioners (NPs) involved in women’s health.

  • CE Approval Period: Through February 28, 2015
  • Estimated Time to Complete This Activity: 1 hour
  • CE Approval Hours: 1.0 Contact Hour of CE Credit, including 1.0 Contact Hour of Pharmacology Content

Educational Objectives
At the conclusion of this activity, clinicians should be better able to:

  • Evaluate specific menopausal and postmenopausal symptoms as they pertain to the individual patient
  • Assess treatment options, dosage, and route of delivery of hormone therapy to meet the individual patient’s needs.
  • Discuss the use of other agents to address the individual patient’s menopausal and postmenopausal symptoms.

Accreditation Statement
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health (NPWH), and has been approved for 1.0 contact hour of CE credit, including 1.0 contact hour of pharmacology content.

Activity Number 13-09J

Faculty Disclosures
NPWH policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity. Faculty are also asked to identify any unlabeled/unapproved uses of drugs or devices made in their presentation.

Ms. Duvall has nothing to disclose.  Dr. Plourd serves on the speakers bureau for Teva Women's Health.

Therapeutics Disclaimer
Participating faculty members determine the editorial content of CE activities; this content does not necessarily represent the views of NPWH or Novo Nordisk. This content has undergone a blinded peer review process for validation of clinical content. Although every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with that of established recommendations of other authorities, national guidelines, FDA approved package inserts, and individual patient characteristics.

Commercial Support
This publication is sponsored in part by an unrestricted educational grant from Novo Nordisk to NPWH.

You must be signed in to access this course. You can sign in at the top right-hand corner of the page. 

**If you are an NPWH member, were once a member, or have taken CE activities with NPWH in the past, you have a username and password in our new system. Please DO NOT create a new account. Creation of multiple accounts could result in loss of CE credits as well as other NPWH services. If you do not remember your username or password, please either click on the "forgot username" or "forgot password" links at the bottom of the sign in screen or call the NPWH office at (202) 543-9693 ext. 1.**


Non-Member/Inactive Member
$0.00 $0.00